New study challenges safety of keyhole surgery for cervical cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with FIGO stage (2018) IA1 (with lymph vascular space invasion), IA2, IB1, IB2 or IIA1 disease * Preoperative histologically confirmed primary adenocarcinoma, squamous cell carcinoma or adenosquamous carcinoma of the uterine cervix * Age ≤ 65 years old; * Physical grading: Karnofsky score ≥ 60 points; * Initial treatment; * Voluntarily joined the study, signed informed consent, willing to comply, and cooperative with follow-up; (Note: The maximum diameter of the cervical lesion is subject to MRI measurements) Exclusion Criteria for Preoperative Patients: * Patients with contraindications to surgery； * Patients who have previously received pelvic/abdominal radiation or chemotherapy；Patients who had received radiotherapy and chemotherapy for other cancers in the past. * Patients with evidence of extra cervical metastases by CT, MRI or PET. * Unable or unwilling to sign informed consent. * Unable or unwilling to comply with research requirements. * Patients with diameter of lymph node metastasis ≥ 2 cm by preoperative MRI. * Patients with pregnancy. * Patients requiring fertility-preserving surgery. * Patients who had previously received subtotal hysterectomy. * Patients participating in other clinical trials. * Patients with other reasons not suitable clinical trials identified by researchers. Exclusion Criteria for Postoperative Patients: * Postoperative pathology: endometrioid adenocarcinoma, clear cell carcinoma, special type adenocarcinoma, neuroendocrine carcinoma (small cell carcinoma), tuberculosis. * Postoperative tumor size ≥ 4 cm. * Patients with abdominal aortic lymph node metastasis. * Patients with severe postoperative complications that are not suitable for adjuvant therapy and affect patient follow-up. * Patients who did not follow requirements for various reasons (except for various complications and deaths caused by tumor recurrence and metastasis). * Situation which researchers believe that treatment should be terminated.